Sumitomo Pharma takes license to CRISPR/Cas9 patent portfolio from ERS Genomics
DUBLIN, April 26, 2022 /PRNewswire/ -- ERS Genomics Limited ("ERS") is pleased to confirm finalization of a license agreement with Sumitomo Pharma Co., Ltd. ("Sumitomo Pharma") granting Sumitomo Pharma non-exclusive access to the fundamental CRISPR/Cas9 intellectual property portfolio held by ERS.
ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual property. Eighty-nine patents are held in over eighty countries, including 3 patents in Japan with broad coverage of the use of CRISPR/Cas9.
ERS CEO Eric Rhodes had the following statement: "We have been working with Sumitomo Pharma's group for some time and are pleased to finally be able to announce this agreement. Sumitomo Pharma has a reputation worldwide for excellence and vision, and we look forward to seeing how CRISPR/Cas9 will enhance their internal research programs and lead to more effective drugs."
Expanding on the regional aspect of the deal, Eric added: "Japan has one of the most developed biotechnology sectors in the world and we hope this partnership with Sumitomo Pharma is a signifier of a growing presence in this country. This represents ERS's 16th license deal in Japan."
Financial details of the agreement are not disclosed.
Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo Corporation, serves as the exclusive agent for ERS Genomics in Japan.
About ERS Genomics
ERS Genomics is a biotechnology company based in Dublin, Ireland. The company was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; companion animal and livestock health; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology.
For additional information, please visit www.ersgenomics.com.
Photo - https://mma.prnewswire.com/media/1803591/ERS_Genomics_Eric_Rhodes.jpg
Logo - https://mma.prnewswire.com/media/1756881/ERS_Genomics_Logo.jpg
Media contact:
Dara O'Donnell
dara.odonnell@ersgenomics.com
+353-1-539 0083
ERS contact:
Yasuto Ando
alliance@summitpharma.co.jp
Share this article